| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abatacept |
10.01.03 |
Non Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Non Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Adalimumab |
13.05.03 |
Non Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA460 : Adalimumab and dexamethasone for treating non-infectious uveitis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA460 : Adalimumab and dexamethasone for treating non-infectious uveitis |
| Adefovir Dipivoxil |
05.03.03.01 |
Non Formulary
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
| Adefovir Dipivoxil |
05.03.03.01 |
Non Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
| Aflibercept |
08.01.05 |
Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA486: Aflibercept for treating choroidal neovascularisation |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Alemtuzumab |
08.02.03 |
Non Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Non Formulary
|
NICE TA156: Anti-D in pregnant women |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for AF |
| Apremilast |
13.05.03 |
Non Formulary
|
NICE TA433 : Apremilast for treating active psoriatic arthritis |
| Apremilast |
13.05.03 |
Non Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Apremilast |
13.05.03 |
Non Formulary
|
NICE TA372: Apremilast for psoriatic arthritis |
| Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA448 : Etelcalcetide for treating secondary hyperparathyroidism |
| Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA456: Baricitinib for moderate to severe rheumatoid arthritis |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for advanced renal cell carcinoma |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
| Basiliximab |
08.02.02 |
Non Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Basiliximab |
08.02.02 |
Non Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Belimumab |
10.01 |
Non Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Bisphosphonates |
09.05.01.02 |
Non Formulary
|
NICE TA464 : Bisphosphonates for treating osteoporos |
| Bivalirudin |
02.08.01 |
Non Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
| Blinatumomab |
08.02 |
Non Formulary
|
NICE TA450 : Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Boceprevir |
05.03.03.02 |
Non Formulary
|
NICE TA253: hepatitis |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: 1st line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
| Bosutinib |
08.01.05 |
Non Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524 : Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib |
08.01.05 |
Non Formulary
|
NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Cangrelor |
02.09 |
Non Formulary
|
NICE TA351: Reducing Artherothrombotic Events |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Carfilzomib |
08.01.05 |
Non Formulary
|
NICE TA457 : Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Ciclosporin 0.1% |
11.08.01 |
Formulary
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
| Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Cladribine |
08.01.03 |
Non Formulary
|
NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis |
| Clearfilm |
A5.02.02 |
Non Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Cobimetinib |
08.02.04 |
Non Formulary
|
NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Colecalciferol 800 units |
09.06.04 |
Non Formulary
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
| Colistimethate inhaler |
05.01.07 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Collagenase |
10.03.01 |
Non Formulary
|
NICE TA459 : Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Conjugated oestrogens + Bazedoxifene |
06.04.01.01 |
Non Formulary
|
NICE TA443 : Obeticholic acid for treating primary biliary cholangitis |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
| Dabrafenib |
08.01.05 |
Non Formulary
|
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Dabrafenib |
08.01.05 |
Non Formulary
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma |
| Daclatasvir |
05.03.03.02 |
Non Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Daclizumab |
08.02.02 |
Non Formulary
|
NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Daratumumab |
08.01.05 |
Non Formulary
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Dasabuvir |
05.03.03.02 |
Non Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Dasatinib |
08.01.05 |
Non Formulary
|
NICE TA241: CML where treatment with imatinib has failed |
| Dasatinib |
08.01.05 |
Non Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Non Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance |
| Dexamethasone intravitreal implant |
11.04.01 |
Non Formulary
|
NICE TA349: Diabetic Macular Oedema |
| Dimethyl fumarate |
08.02.04 |
Non Formulary
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
| Dimethyl fumarate |
08.02.04 |
Non Formulary
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Docetaxel |
08.01.05 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
| Dornase Alfa |
03.07 |
Formulary
|
NICE NG78: Cystic fibrosis: diagnosis and management |
| Doxorubicin |
08.01.02 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation |
| Eltrombopag |
09.01.04 |
Non Formulary
|
NICE TA293: Eltrombopag for treating chronic ITP |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
| Emtricitabine + rilpivirine + tenofovir alafenamide |
05.03.01 |
Non Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
| Entecavir |
05.03.03.01 |
Non Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Entecavir |
05.03.03.01 |
Non Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for prostate cancer |
| Eplerenone |
02.02.03 |
Formulary
|
NICE NG106: Chronic heart failure in adults: diagnosis and management |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
| Etanercept |
13.05.03 |
Non Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Everolimus |
08.01.05 |
Non Formulary
|
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exenatide |
06.01.02.03 |
Formulary
|
Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes |
| Exenatide prolonged release |
06.01.02.03 |
Non Formulary
|
NICE TA248: MR exenatide |
| Febuxostat |
10.01.04 |
Non Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
| Fingolimod |
08.02.04 |
Non Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
| Fulvestrant |
08.03.04.01 |
Non Formulary
|
NICE YA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer |
| Fulvestrant |
08.03.04.01 |
Non Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Glatiramer Acetate |
08.02.04 |
Non Formulary
|
NICE CG32: Glatiramer for the treatment of MS |
| Glecaprevir / Pibrentasvir |
05.03.03.02 |
Non Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA220: Golimumab for the treatment of psoriatic arthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Non Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| Idelalisib |
08.01.05 |
Non Formulary
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
13.05.03 |
Non Formulary
|
NICE TA134: Infliximab for psoriasis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Injection Device |
06.01.01.03 |
Non Formulary
|
NICE TA442 : Ixekizumab for treating moderate to severe plaque psoriasis |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Ipilimumab |
08.01.05 |
Non Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Non Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ipilimumab |
08.01.05 |
Non Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ivabradine |
02.06.03 |
Formulary
|
NICE TA267: Ivabradine for treating chronic heart failure |
| Ivabradine |
02.06.03 |
Non Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Ixazomib |
08.01.05 |
Formulary
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Labetalol |
02.04 |
Formulary
|
NICE NG133: Hypertension in pregnancy: diagnosis and management |
| Lamivudine |
05.03.01 |
Non Formulary
|
NICE CG165: Chronic Hepatitis B |
| Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Ledipasvir and Sofosbuvir |
05.03.03.02 |
Non Formulary
|
NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Ledipasvir and Sofosbuvir |
05.03.03.02 |
Non Formulary
|
NICE TA430 : Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Lenalidomide |
08.02.04 |
Formulary
|
Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy TA171 |
| Lenalidomide |
08.02.04 |
Formulary
|
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality TA322 |
| Lenvatinib |
08.01.05 |
Non Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Lesinurad |
10.01.04 |
Non Formulary
|
NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout |
| Lubiprostone |
01.06.07 |
Non Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lumacaftor + Ivacaftor |
03.07 |
Non Formulary
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
| Mannitol inhalation |
03.07 |
Non Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation |
| Mepolizumab |
03.04.02 |
Non Formulary
|
NICE TA431 : Mepolizumab for treating severe refractory eosinophilic asthma |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis; management in primary and secondary care. |
| Mifamurtide |
08.02.04 |
Non Formulary
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
| Milrinone |
02.01.02 |
Non Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
| Nalmefene |
04.10.01 |
Restricted Use
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Naltrexone/ bupropion |
04.05.01 |
Non Formulary
|
Nice TA494: Naltrexone–bupropion for managing overweight and obesity |
| Natalizumab |
08.02.04 |
Non Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
| Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nintedanib |
03.11 |
Non Formulary
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
03.11 |
Non Formulary
|
NICE TA347: Recurrent non-small-cell lung cancer |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Obinutuzumab |
08.02.03 |
Non Formulary
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Obinutuzumab |
08.02.03 |
Non Formulary
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
| Ofatumumab |
08.02.03 |
Non Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
| Olaparib |
08.02.04 |
Formulary
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Omalizumab for treating allergic asthma |
| Ombitasvir/ paritaprevir/ ritonavir |
05.03.03.02 |
Non Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Non Formulary
|
NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine |
| Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Panitumumab |
08.01.05 |
Non Formulary
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panobinostat |
08.01.05 |
Non Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Pazopanib |
08.01.05 |
Non Formulary
|
NICE TA215: Pazopanib in renal cell cancer |
| Pegaspargase |
08.01 |
Non Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA96: Hepatitis B - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA300: Hepatitis C - peginterferon alfa |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA531 : Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Perampanel |
04.08.01 |
Non Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Pertuzumab |
08.01.05 |
Non Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Non Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pirfenidone |
03.11 |
Formulary
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
| Pixantrone |
08.01.02 |
Non Formulary
|
NICE TA306: Pixantrone monotherapy |
| Pomalidomide |
08.02.04 |
Non Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Pomalidomide |
08.02.04 |
Non Formulary
|
NICE TA388: Pomalidomide for myeloma |
| Ponatinib |
08.01.05 |
Non Formulary
|
NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Prucalopride for the treatment of chronic constipation in women |
| Radium-223 dichloride |
08.03.04.02 |
Non Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Radium-223 dichloride |
08.03.04.02 |
Non Formulary
|
NICE TA376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
| Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Regorafenib |
08.01.05 |
Non Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Reslizumab |
03.04.02 |
Non Formulary
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Non Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Rifaximin |
05.01.07 |
Formulary
|
Rifaximin for preventing episodes of overt hepatic encephalopathy TA337 |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
| Rituximab (rheumatology) |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA461 : Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources) |
| Sarilumab |
10.01.03 |
Non Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
13.05.03 |
Non Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab |
13.05.03 |
Non Formulary
|
NICE TA350: Plaque Psoriasis |
| Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
| Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
| Sofosbuvir |
05.03.03.02 |
Non Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir and Velpatasvir |
05.03.03.02 |
Non Formulary
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Somatropin for growth failure in children |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
| Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Talimogene laherparepvec |
08.01.05 |
Non Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tegafur with Uracil |
08.01.03 |
Non Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telaprevir |
05.03.03.02 |
Non Formulary
|
NICE TA252: Telaprevir in hepatitis C |
| Temozolomide |
08.01.05 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
| Temozolomide |
08.01.05 |
Non Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for relapsing remitting MS |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tobramycin inhaler |
05.01.04 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA247:Tocilizumab in RA |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tofacitinib citrate |
10.01.03 |
Non Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Tolvaptan |
06.05.02 |
Non Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Tolvaptan |
06.05.02 |
Non Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trametinib |
08.01.05 |
Non Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab emtansine |
08.01.05 |
Non Formulary
|
NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan |
| Ustekinumab |
13.05.03 |
Non Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Non Formulary
|
NICE TA180: Psoriasis - ustekinumab |
| Ustekinumab |
13.05.03 |
Non Formulary
|
NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopl |
| Ustekinumab |
13.05.03 |
Non Formulary
|
NICE TA456 : Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vemurafenib |
08.01.05 |
Non Formulary
|
NICE TA269: Vemurafenib for treating malignant melanoma |
| Venetoclax |
08.01.05 |
Non Formulary
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
| Verteporfin |
11.08.02 |
Non Formulary
|
NICE TA68: Photodynamic therapy for age related macular degeneration |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
| Vismodegib |
08.01.05 |
Non Formulary
|
NICE TA489: Vismodegib for treating basal cell carcinoma |
| Vitamin B & C high potency injection |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Vitamin B & C high potency injection |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Vortioxetine |
04.03.04 |
Formulary
|
NICE TA367 - Vortioxetine for treating major depressive episodes |
| Zolpidem |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
